Oruka Therapeutics Inc (ORKA) USD0.001

Sell:$10.80Buy:$10.96$0.52 (4.56%)

Prices delayed by at least 15 minutes
Sell:$10.80
Buy:$10.96
Change:$0.52 (4.56%)
Prices delayed by at least 15 minutes
Sell:$10.80
Buy:$10.96
Change:$0.52 (4.56%)
Prices delayed by at least 15 minutes

Company Information

About this company

Oruka Therapeutics, Inc., formerly ARCA biopharma, Inc., is a biotechnology company. The Company is engaged in developing novel biologics designed for the treatment of chronic skin diseases, including plaque psoriasis. It is advancing a proprietary portfolio of potential antibodies that target the core mechanisms underlying plaque psoriasis and other dermatologic and inflammatory diseases. The Company’s lead programs include ORKA-001 and ORKA-002, which are designed to block cytokines in the pathogenesis of psoriasis and other inflammatory diseases. ORKA-001 is a potentially monoclonal antibody designed to inhibit IL-23p19 for the treatment of psoriasis. ORKA-001 targets the p19 subunit of interleukin-23 (IL-23p19). ORKA-002 is a potentially monoclonal antibody designed to inhibit IL-17A/F for the treatment of psoriasis, psoriatic arthritis, and other conditions. ORKA-002 targets interleukin-17A and interleukin-17F (IL-17A/F).

Key people

Lawrence Otto Klein
President, Chief Executive Officer, Director
Arjun Agarwal
Senior Vice President - Finance, Treasurer
Paul T. Quinlan
General Counsel, Secretary
Joana Goncalves
Chief Medical Officer
Samarth Kulkarni
Non-Executive Independent Chairman of the Board
Kristine M. Ball
Independent Director
Carl Dambkowski
Independent Director
Peter Harwin
Independent Director
Cameron Turtle
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    United States
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    US6876041087
  • Market cap
    $398.98m
  • Employees
    4
  • Shares in issue
    35.00m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.